These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 35941631)

  • 1. Enhanced passive safety surveillance of a quadrivalent inactivated split virion influenza vaccine in Finland during the influenza season 2020/21.
    Syrkina O; Inamdar A; Wague S; Monfredo C; Nissilä M; Chabanon AL; Serradell L
    BMC Public Health; 2022 Aug; 22(1):1506. PubMed ID: 35941631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older.
    Dos Santos G; Devadiga R; Kim CS; Bang J
    Drug Saf; 2024 Apr; 47(4):365-375. PubMed ID: 38483767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain for the 2018/19 Season: Interim Analysis.
    Dos Santos G; Shende V; Damaso S; Yeakey A
    Adv Ther; 2019 Dec; 36(12):3340-3355. PubMed ID: 31595482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.
    Haber P; Moro PL; Lewis P; Woo EJ; Jankosky C; Cano M
    Vaccine; 2016 May; 34(22):2507-12. PubMed ID: 27015735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passive enhanced safety surveillance of GSK's quadrivalent seasonal influenza vaccine in Belgium, Germany and Spain, an observational study: protocol for the 2018/2019 influenza season.
    Dos Santos G; Yeakey A; Shende V; Smith K; Lin F; Zandman-van-Dijk E; Damaso S; Schmidt A
    BMJ Open; 2019 Aug; 9(8):e028043. PubMed ID: 31427321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season.
    de la Cueva IS; Gerber JE; Hastie A; Brotons C; Panzer F; Pirçon JY; Talsma P; Eckermann T; Nikic V; Gomez XM; Alsdurf H
    Drug Saf; 2024 Jun; ():. PubMed ID: 38949714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza burden averted with a cell-based quadrivalent seasonal influenza vaccine compared with egg-based quadrivalent seasonal influenza vaccine.
    McGovern I; Taylor A; Sardesai A; Toro-Diaz H; Haag M
    Expert Rev Vaccines; 2024; 23(1):371-379. PubMed ID: 38494917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model.
    Pahmeier K; Speckemeier C; Neusser S; Wasem J; Biermann-Stallwitz J
    Pharmacoeconomics; 2023 Nov; 41(11):1539-1550. PubMed ID: 37434014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Safety evaluation of simultaneous administration of quadrivalent influenza split virion vaccine and 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and older].
    Zhu ZK; Lu X; Tang WQ; Sun JW; Shen L; Chen QL; Liu HX; Yu Y; Gu W; Zhao YW; Xie Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Sep; 57(9):1412-1417. PubMed ID: 37554083
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults.
    Montomoli E; Torelli A; Manini I; Gianchecchi E
    Vaccines (Basel); 2018 Mar; 6(1):. PubMed ID: 29518013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European "Covid Vaccine Monitor" Active Surveillance Study.
    Bellitto C; Luxi N; Ciccimarra F; L'Abbate L; Raethke M; van Hunsel F; Lieber T; Mulder E; Riefolo F; Villalobos F; Thurin NH; Marques FB; Morton K; O'Shaughnessy F; Sonderlichová S; Farcas A; Janneke GE; Sturkenboom MC; Trifirò G
    Drug Saf; 2024 Jun; ():. PubMed ID: 38907947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active surveillance for adverse events of influenza vaccine safety in elderly cancer patients using self-controlled tree-temporal scan statistic analysis.
    Jeong NY; Kim CJ; Park SM; Kim YJ; Lee J; Choi NK
    Sci Rep; 2023 Aug; 13(1):13346. PubMed ID: 37587127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reply letter to "Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal".
    Hadigal S; Colombo L; Cook J
    J Med Econ; 2023; 26(1):933-934. PubMed ID: 37450279
    [No Abstract]   [Full Text] [Related]  

  • 14. Erratum: Conserved and host-specific features of influenza virion architecture.
    Hutchinson EC; Charles PD; Hester SS; Thomas B; Trudgian D; Martínez-Alonso M; Fodor E
    Nat Commun; 2015 Feb; 6():6446. PubMed ID: 25687574
    [No Abstract]   [Full Text] [Related]  

  • 15. Healthy vaccinee effect in practice.
    Straka R; Furst T; Janosek J
    Pol Arch Intern Med; 2024 May; 134(5):. PubMed ID: 38804815
    [No Abstract]   [Full Text] [Related]  

  • 16. Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2022/23 influenza season.
    Machado MAA; Gandhi-Banga S; Gallo S; Cousseau TG; Byrareddy RM; Nissilä M; Schelling J; Monfredo C
    Hum Vaccin Immunother; 2024 Dec; 20(1):2322196. PubMed ID: 38448394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three seasons of enhanced safety surveillance of a cell culture-based quadrivalent influenza vaccine.
    Domnich A; Amicizia D; Lai PL; Ogliastro M; Piedrahita-Tovar M; Orsi A; Icardi G; Panatto D
    Hum Vaccin Immunother; 2023 Aug; 19(2):2261689. PubMed ID: 37787067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-Marketing Safety Surveillance of Quadrivalent Influenza Vaccine (VaxigripTetra) in Children Aged 6 to 35 Months in South Korea.
    Choe S; Talanova O; Shin S; Syrkina O; Fournier M
    Infect Dis Ther; 2023 Jun; 12(6):1715-1723. PubMed ID: 37300743
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.